Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
1. Pfizer and Novo Nordisk compete to acquire Metsera. 2. Novo Nordisk's $10 billion bid is currently superior, according to Metsera. 3. Pfizer seeks to block Metsera's termination of the merger deal. 4. Metsera's drugs could enhance Pfizer's entry into the obesity market. 5. Regulatory risks and market competition concern analysts regarding the deals.